{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:49:49Z","timestamp":1791931789688,"version":"4.3.4"},"reference-count":26,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2018,10,31]],"date-time":"2018-10-31T00:00:00Z","timestamp":1540944000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0206722","type":"journal-article","created":{"date-parts":[[2018,10,31]],"date-time":"2018-10-31T17:55:46Z","timestamp":1541008546000},"page":"e0206722","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":25,"title":["Safety and efficacy of low dose pioglitazone compared with standard dose pioglitazone in type 2 diabetes with chronic kidney disease: A randomized controlled trial"],"prefix":"10.1371","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8881-0942","authenticated-orcid":true,"given":"Bancha","family":"Satirapoj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khanin","family":"Watanakijthavonkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ouppatham","family":"Supasyndh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,10,31]]},"reference":[{"issue":"4","key":"ref1","doi-asserted-by":"crossref","first-page":"e475","DOI":"10.1097\/MD.0000000000000475","article-title":"Epidemiological study of chronic kidney disease progression: a large-scale population-based cohort study","volume":"94","author":"P Vejakama","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"ref2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000382028","article-title":"Prevalence and Management of Diabetic Nephropathy in Western Countries","volume":"1","author":"B Satirapoj","year":"2015","journal-title":"Kidney Dis (Basel)"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/978-1-4614-5441-0_11","article-title":"Nephropathy in diabetes","volume":"771","author":"B Satirapoj","year":"2012","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"ref4","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2174\/138920011794520053","article-title":"Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice","volume":"12","author":"M Abe","year":"2011","journal-title":"Curr Drug Metab"},{"issue":"13","key":"ref5","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.2165\/00003495-200363130-00004","article-title":"Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence","volume":"63","author":"M Diamant","year":"2003","journal-title":"Drugs"},{"issue":"1","key":"ref6","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1038\/s41598-017-01965-0","article-title":"Efficacy and safety of thiazolidinediones in diabetes patients with renal impairment: a systematic review and meta-analysis","volume":"7","author":"W Wang","year":"2017","journal-title":"Sci Rep"},{"issue":"4","key":"ref7","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1046\/j.1365-2125.2003.01785.x","article-title":"The pharmacokinetics of pioglitazone in patients with impaired renal function","volume":"55","author":"K Budde","year":"2003","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"ref8","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1093\/ndt\/gft462","article-title":"Glucose-lowering drugs in patients with chronic kidney disease: a narrative review on pharmacokinetic properties","volume":"29","author":"P Arnouts","year":"2014","journal-title":"Nephrol Dial Transplant"},{"issue":"23","key":"ref9","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1161\/01.CIR.0000103683.99399.7E","article-title":"Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association","volume":"108","author":"RW Nesto","year":"2003","journal-title":"Circulation"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"943614","DOI":"10.1155\/2008\/943614","article-title":"Renal and vascular mechanisms of thiazolidinedione-induced fluid retention","volume":"2008","author":"T Yang","year":"2008","journal-title":"PPAR Res"},{"issue":"1","key":"ref11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1177\/1470320312452028","article-title":"Effects of low-dose pioglitazone on glucose control, lipid profiles, renin-angiotensin-aldosterone system and natriuretic peptides in diabetic patients with coronary artery disease","volume":"14","author":"S Kurisu","year":"2013","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"3","key":"ref12","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1507\/endocrj.K05-067","article-title":"Safety and efficacy of low-dose pioglitazone (7.5 mg\/day) vs. standard-dose pioglitazone (15 mg\/day) in Japanese women with type 2 diabetes mellitus","volume":"53","author":"T Majima","year":"2006","journal-title":"Endocr J"},{"issue":"2","key":"ref13","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/ajcn\/87.2.332","article-title":"Ability of new octapolar bioimpedance spectroscopy analyzers to predict 4-component-model percentage body fat in Hispanic, black, and white adults","volume":"87","author":"AL Gibson","year":"2008","journal-title":"Am J Clin Nutr"},{"issue":"5","key":"ref14","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1053\/j.ajkd.2012.07.005","article-title":"KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update","volume":"60","year":"2012","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 2","key":"ref15","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1093\/ndt\/gfv100","article-title":"Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 mL\/min)","volume":"30","year":"2015","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"ref16","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2337\/diacare.25.3.517","article-title":"Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes","volume":"25","author":"Y Miyazaki","year":"2002","journal-title":"Diabetes Care"},{"issue":"11","key":"ref17","first-page":"36","article-title":"Effect of Low (7.5 mg\/day), Standard (15 mg\/day) and High (30 mg\/day) Dose Pioglitazone Therapy on Glycemic Control and Weight Gain in Recently-Diagnosed Type 2 Diabetes Patients","volume":"63","author":"V Panikar","year":"2015","journal-title":"J Assoc Physicians India"},{"issue":"3","key":"ref18","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1016\/j.diabres.2015.05.030","article-title":"Effect of low dose pioglitazone on glycemic control and insulin resistance in Type 2 diabetes: A randomized, double blind, clinical trial","volume":"109","author":"S Rajagopalan","year":"2015","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"ref19","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/sj.ki.5002442","article-title":"Thiazolidinediones and fluid retention","volume":"72","author":"K Kiryluk","year":"2007","journal-title":"Kidney Int"},{"issue":"7","key":"ref20","doi-asserted-by":"crossref","first-page":"e6112","DOI":"10.1371\/journal.pone.0006112","article-title":"Adding pioglitazone to insulin containing regimens in type 2 diabetes: systematic review and meta-analysis","volume":"4","author":"C Clar","year":"2009","journal-title":"PLoS One"},{"issue":"2","key":"ref21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1177\/030006059902700201","article-title":"Troglitazone combination therapy in obese type 2 diabetic patients poorly controlled with alpha-glucosidase inhibitors","volume":"27","author":"Y Bando","year":"1999","journal-title":"J Int Med Res"},{"issue":"2","key":"ref22","doi-asserted-by":"crossref","first-page":"288","DOI":"10.2337\/diacare.22.2.288","article-title":"Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes","volume":"22","author":"IE Kelly","year":"1999","journal-title":"Diabetes Care"},{"issue":"3","key":"ref23","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0168-8227(01)00319-9","article-title":"Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation\u2014double-blind placebo-controlled trial","volume":"54","author":"T Nakamura","year":"2001","journal-title":"Diabetes Res Clin Pract"},{"issue":"11","key":"ref24","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.2337\/diacare.23.11.1605","article-title":"Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group","volume":"23","author":"S Aronoff","year":"2000","journal-title":"Diabetes Care"},{"issue":"3","key":"ref25","doi-asserted-by":"crossref","first-page":"230","DOI":"10.4093\/dmj.2016.40.3.230","article-title":"Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin","volume":"40","author":"JH Kim","year":"2016","journal-title":"Diabetes Metab J"},{"issue":"1","key":"ref26","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000471765","article-title":"Sodium-Glucose Cotransporter 2 Inhibitors with Renoprotective Effects","volume":"3","author":"B Satirapoj","year":"2017","journal-title":"Kidney Dis (Basel)"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0206722","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T16:17:59Z","timestamp":1589041079000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0206722"}},"subtitle":[],"editor":[{"given":"Stephen L","family":"Atkin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,10,31]]},"references-count":26,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2018,10,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0206722","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,31]]}}}